ICH E7 requirements and how they are translated in practice

Kristina Dunder MD, PhD
Alternate CHMP member
Medical Products Agency, Sweden

LÄKEMEDELSVERKET
MEDICAL PRODUCTS AGENCY

ICH; International Conference of Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use

- **6 parties (FDA, EMA, MHLW, PhRMA, EFPIA & JPMA)**

- **Make recommendations on ways to achieve greater harmonisation in the interpretation and application of technical guidelines and requirements for product registration**

Guidance for the Assessment of Geriatric Data; ICH E7

emeA European Medicines Agency

March 1994
CPMP/ICH/379/95

> **ICH Topic E 7**
> **Studies in Support of Special Populations: Geriatrics**

Step 5

> **NOTE FOR GUIDANCE ON STUDIES IN SUPPORT OF SPECIAL**
> **POPULATIONS: GERIATRICS**
> **(CPMP/ICH/379/95)**

ICH Concept Paper for Q&A E7 (2008)

- **Importance of geriatric data (from the entire spectrum of the geriatric patient population) in a drug evaluation program has increased**

  - Increasing size of the geriatric population (including patients 75 and older)
  - Recent advances in pharmacokinetics and pharmacodynamics since the ICH E7 guideline was established in 1994

- **Need for a Q&A document to updated the recommendations**

ICH Concept Paper; important issues

- **Number and age distribution of expected elderly participants in a given indication development and the criteria on which these figures are based**

- **Plan a development approach**

- **Describe specific elements in the assessment of the risks and benefits of the drug in the elderly, including common co-morbidities and concomitant therapies**

- **Specific endpoints in the elderly population**

- **Usefulness of specific pharmacokinetic studies versus population pharmacokinetics**

- **What could be addressed post-authorisation?**

1.Why do we need an adequate representation of geriatric patients in the clinical database?

Geriatric patients can respond differently from younger patients to drug therapy in a number of ways and such differences can be greater in patients 75 years and older:

a) The geriatric population has age-related physiological changes that can affect the pharmacokinetics of the drug, and the pharmacodynamic response to the drug, both of which can influence the drug-response and the dose response relationship.

b) Geriatric patients are more prone to adverse effects since they often have co-morbidities and are taking concomitant therapies that could interact with the investigational drug. The adverse effects can be more severe, or less tolerated, and have more serious consequences than in the non-geriatric population.

With the increasing size of the geriatric population (including patients 75 and older) and in view of the recent advances in pharmacokinetics and pharmacodynamics since the ICH E7 guideline was established in 1993, the importance of geriatric data (from the entire spectrum of the geriatric patient population) in a drug evaluation program has increased.

Not all potential differences in pharmacokinetics, pharmacodynamics, disease-drug, drug-drug interactions and clinical response that can occur in the geriatric population can be predicted from non-geriatric populations, as the geriatric patients are far more likely to have multiple illnesses and to be receiving multiple drugs. Therefore, to assess the benefit/risk balance of a drug that will be used in the geriatric population, these patients should be appropriately represented in clinical trials.

Translation into practice

- **Do older patients constitute a "special population"?**
  - "Healthy" elderly;
    - Efficacy/safety data can be extrapolated from younger people

  - Age related differences covered by PK studies (renal and hepatic impairments, drug interactions) included in MAA
    - Need some clinical data for confirmation

  - Patients with comorbidities/comedications ("frail")
    - Extrapolation less reliable due to unknown factors
    - Stand-alone data needed
    - Included in trials or separate study???

2. What should be taken into account when estimating an adequate representation of geriatric patients to be included in the clinical database?

It is very important to ensure, to the extent possible, that the population included in the clinical development program is representative of the target patient population. As stated in the current ICH E7 guideline, estimates of the prevalence of the disease to be treated by age or examination of the age distribution of usage for other drugs of the same class or for the same indication should be provided by the applicant. This will indicate the expected use of the drug and should influence the number of geriatric patients to be included in the marketing application.

The current guideline states, "for drugs used in diseases not unique to, but present in the elderly, a minimum of 100 patients would usually allow detection of clinically important differences". Given the increasing prevalence and the growing recognition of the complexity of the geriatric population, including concomitant therapies and co-morbidities, it would usually be appropriate to include more than 100 geriatric patients in the Phase 2 and 3 databases and include patients over the entire spectrum of the geriatric patient population.

In the marketing application, depending on the numbers of patients, data should be presented for various age groups (for example <65, 65-74, 75-84 and > 85) to assess the consistency of the treatment effect and safety profile in these patients with the non-geriatric patient population.
As single trials may not have sufficient numbers of geriatric patients to allow such analyses, these will often need to be carried out on pooled data. Any such analyses will need to consider consistency across studies.

Translation into practice

- **E7**

  – "for drugs used in diseases not unique to, but present in the elderly, a minimum of 100 patients would usually allow detection of clinically important differences"

- **Q&A; number of elderly not specified**

  - Population reflect target population

  - Usually appropriate to include more than 100

  - Important include patients > 75; surrogate for fraility

  - How many patients needed to show " consistency of the treatment effect and safety profile"?

    – Too low number; confidence intervals wide, point esimate unreliable

    – Case by case, depending on mechanism, target population

    – Scientific advice recommended

eCTD Module		Age 65-74	Age 75-84	Age 85+
5.3.1 *Biopharmaceutic Studies*		number / total number	number / total number	number / total number
5.3.3 *Human PK Studies*	**5.3.3.1** *Healthy and Initial Tolerability Studies*	number / total number	number / total number	number / total number
	5.3.3.2 *Patient PK and Initial Tolerability Studies*	number / total number	number / total number	number / total number
	5.3.3.3 *Studies*	number / total number	number / total number	number / total number
	5.3.3.4 *Studies*	number / total number	number / total number	number / total number
5.3.4 *Human PD Studies*	**5.3.4.1** *Healthy and PK/PD Studies*	number / total number	number / total number	number / total number
	5.3.4.2 *Patient PK and PK/PD Studies*	number / total number	number / total number	number / total number
5.3.5 *Efficacy and Safety Studies*	**5.3.5.1** *Controlled Clinical Studies*	number / total number	number / total number	number / total number
	5.3.5.2 *Uncontrolled Clinical Studies*	number / total number	number / total number	number / total number
	5.3.5.4 *Other Clinical Studies*	number / total number	number / total number	number / total number

In order to allow appropriate evaluation of the available data, and inclusion of relevant information about geriatric patients in the EPAR, SPC and PIL the following table should be filled by the Applicant. The Applicant should comment on how the data have been summarised, in order to avoid a signal dilution.

AE Table

	Age <65 yrs	65-74 yrs	75-84 yrs	85 +
Total				
Fatal				
Serious				
Withdrawal				
CNS (confusion/extrapyramidal)				
AE related to falling				
CV events				
Cerebrovascular events				
Infections				

3. Are there any special patient populations or characteristics that are particularly important to address in the planning of the clinical development program?

Geriatric patients often have co-morbidities and concomitant therapies that could interact with the investigational drug and make patients more likely to have undesirable effects and interactions. Therefore, it is important to assess the safety and efficacy of a drug in such patients, and to design a study with inclusion/exclusion criteria that allows their participation. There may exist a reluctance to include vulnerable geriatric patients at high risk of adverse outcomes (so-called "frail" geriatric patients). However, care in randomization should allow the appropriate attribution of findings either to the investigational drug or to other factors.

This applies both to drugs intended for the geriatric patient population and for drugs used in diseases present in, but not unique to, the geriatric population.

4. What should be considered for the clinical development program to adequately characterize the safety and efficacy of a drug for a marketing application?

An appropriate representation of the geriatric population (including patients with concomitant therapies and co-morbidities) should be enrolled in the clinical development program to adequately characterize efficacy and safety in the geriatric population and allow for comparisons with the non-geriatric population. This information would ordinarily be expected in a marketing application.
 In general it is preferable to include both non-geriatric and geriatric patients in the same study(ies), which can facilitate observation of age-related differences. In some cases a separate study in the geriatric population can be preferable.

Every effort should be made to include geriatric patients using concomitant therapies and with co-morbidities in the pre-marketing clinical development program. In some cases, enrolment of these patients can be challenging and it could be appropriate to collect data post-marketing. However, the adequacy of, and the need for, data in these patients should be considered during drug development and discussed in the marketing application submission. Where enrolment of geriatric patients has been insufficient despite the efforts of the applicant, a specific plan to collect data post-marketing should be discussed during development and presented in the marketing application.

Information relevant to the geriatric patient population, including any limitations, should be reflected in the product labelling.

LÄKEMEDELSVERKET
MEDICAL PRODUCTS AGENCY

approvals • authorisation • clinical trials • communication • competence • cosmtics • dialogue • directives • efficacy • environment • evaluation • guidelines • harmonisation • health economics • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • narcotics • public health • quality • registration • regulations • reliability • risk/benefit • safety • scientific • standardisation • transparency • vigilance • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmtics • dialogue • directives • efficacy • environment • evaluation • guidelines • harmonisation • health economics • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • narcotics • public health

Translation into practice

- **Inclusion of frail patients pre- or postmarketing?**
  - Data expected in the MAA
  - If acceptable postmarketing will depend on target population
    - Specific plan; condition in RMP/Annex 2
    - Practical problems remain post marketing

- **Scientific advice**
  - The need to include frail patients; pre/postmarketing
  - Frailty evaluation tools (input from geriatric expert group GEG)
  - Separate study in some cases

- **Reflected in product information, EPAR**
  - Data in patients >75 years

5. Are there concerns related to the data specific to the geriatric population that could be considered in the planning of the clinical studies?

Depending on the mechanism of action of the drug and/or the characteristics of the disease, certain specific adverse events and age-related efficacy endpoints should be actively sought in the geriatric population, e.g. effects on cognitive function, balance and falls, urinary incontinence or retention, weight loss and sarcopenia. This may require specific testing, e.g. for cognitive function. Applicants should also refer to disease specific guidelines for specific recommendations concerning the evaluation of both efficacy and safety in geriatric patients.

Translation in to practice

- **Depend on the characteristics of disease and MOA**

- **Input from geriatric expert group (GEG)**

  – Relevant endpoints

- **Strengten existing disease specific guidelines**

6. In light of recent advances in the field of pharmacokinetics and assessment of drug-drug interactions since the ICH E7 guideline was established, what studies should be considered when developing a drug that will be used in geriatric patients?

The pharmacokinetics in geriatric patients (over the entire spectrum of the geriatric patient population) should be evaluated to identify age-related differences that are not explained by other factors such as reduced renal function or weight differences. The potential influence of impaired renal/hepatic function as well as potential drug interactions is often assessed in studies with non-geriatric subjects.

Population pharmacokinetic analysis could provide the requested data if a sufficient number of patients in different age ranges (including patients >65 and >75 years) are included in the clinical trials. The applicability of population pharmacokinetics is dependent on several factors, e.g. the representation of the target population, the pharmacokinetics of the drug, dosing regimens and analytical requirements.

A specific pharmacokinetic study comparing non-geriatric and geriatric subjects in the same study (matched for relevant covariates, e.g. weight, sex) could achieve the same goals.

More details on the pharmacokinetic approach (population pharmacokinetics, the appropriate design of a specific pharmacokinetic study) and assessment of drug-drug interactions can be discussed with the regulatory agencies.

Translation into practice

- **Purpose of separate PK study**
  - Influence of "unknowns"
  - Very elderly must be included
- **Other relevant guidelines**
  - Investigation of drug interactions

  - Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impaired Hepatic Function

  - Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impaired Renal Function

LÄKEMEDELSVERKET
MEDICAL PRODUCTS AGENCY

approvals • authorisation • clinical trials • communication • competence • cosmtics • dialogue • directives • efficacy • environment • evaluation • guidelines • harmonisation • health economics • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • narcotics • public health • quality • registration • regulations • reliability • risk/benefit • safety • scientific • standardisation • transparency • vigilance • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmtics • dialogue • directives • efficacy • environment • evaluation • guidelines • harmonisation • health economics • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • narcotics • public health

Conclusion; Main messages E7 Q&A

- **<u>More than 100</u> geriatric patients may be needed**

- **Data should be presented for the <u>entire age spectrum</u>**

- **<u>Every effort</u> to include geriatric patients with concomitant therapies and co-morbidities in the <u>premarketing</u> clinical development program**

- **Certain <u>specific adverse events</u> should be looked for in the geriatric population**

- **Population PK <u>or</u> specific PK study**